These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35173709)

  • 1. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
    Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
    Front Immunol; 2021; 12():804988. PubMed ID: 35173709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
    Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
    Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
    Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
    Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
    Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
    Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
    Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
    J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy.
    Ruggeri L; Parisi S; Urbani E; Curti A
    Front Immunol; 2015; 6():479. PubMed ID: 26528283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.
    Parisi S; Lecciso M; Ocadlikova D; Salvestrini V; Ciciarello M; Forte D; Corradi G; Cavo M; Curti A
    Front Immunol; 2017; 8():1330. PubMed ID: 29097997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with double-bright (CD56
    Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
    Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
    Lemoli RM; Parisi S; Curti A
    Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.
    Ruggeri L; Mancusi A; Capanni M; Urbani E; Carotti A; Aloisi T; Stern M; Pende D; Perruccio K; Burchielli E; Topini F; Bianchi E; Aversa F; Martelli MF; Velardi A
    Blood; 2007 Jul; 110(1):433-40. PubMed ID: 17371948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
    Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.